Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions.

Villatoro S, Mayo-de-Las-Casas C, Jordana-Ariza N, Viteri-Ramírez S, Garzón-Ibañez M, Moya-Horno I, García-Peláez B, González-Cao M, Malapelle U, Balada-Bel A, Martínez-Bueno A, Campos R, Reguart N, Majem M, Blanco R, Blasco A, Catalán MJ, González X, Troncone G, Karachaliou N, Rosell R, Molina-Vila MA.

Mol Oncol. 2019 Sep 17. doi: 10.1002/1878-0261.12574. [Epub ahead of print]

2.

Stromal markers of activated tumor associated fibroblasts predict poor survival and are associated with necrosis in non-small cell lung cancer.

Alcaraz J, Carrasco JL, Millares L, Luis IC, Fernández-Porras FJ, Martínez-Romero A, Diaz-Valdivia N, De Cos JS, Rami-Porta R, Seijo L, Ramírez J, Pajares MJ, Reguart N, Barreiro E, Monsó E.

Lung Cancer. 2019 Sep;135:151-160. doi: 10.1016/j.lungcan.2019.07.020. Epub 2019 Jul 24.

3.

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Non-Small Cell Lung Carcinoma Patients: the ROSING Study.

Conde E, Hernandez S, Martinez R, Angulo B, De Castro J, Collazo-Lorduy A, Jimenez B, Muriel A, Mate JL, Moran T, Aranda I, Massuti B, Rojo F, Domine M, Sansano I, Garcia F, Felip E, Mancheño N, Juan O, Sanz J, Gonzalez-Larriba JL, Atienza-Cuevas L, Arriola-Arellano E, Abdulkader I, Garcia-Gonzalez J, Camacho C, Rodriguez-Abreu D, Teixido C, Reguart N, Gonzalez-Piñeiro A, Lazaro-Quintela M, Lozano MD, Gurpide A, Gomez-Roman J, Lopez-Brea M, Pijuan L, Salido M, Arriola E, Company A, Insa A, Esteban-Rodriguez I, Saiz M, Azkona E, Alvarez R, Artal A, Plaza ML, Aguiar D, Enguita AB, Benito A, Paz-Ares L, Garrido P, Lopez-Rios F.

J Thorac Oncol. 2019 Jul 23. pii: S1556-0864(19)30562-3. doi: 10.1016/j.jtho.2019.07.005. [Epub ahead of print]

4.

Immune-Related Adverse Events and Outcomes in Patients with Advanced Non-Small Cell Lung Cancer: A Predictive Marker of Efficacy?

Remon J, Reguart N, Auclin E, Besse B.

J Thorac Oncol. 2019 Jun;14(6):963-967. doi: 10.1016/j.jtho.2019.02.031. Epub 2019 Apr 23. No abstract available.

PMID:
31027971
5.

Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report.

Reyes R, Mayo-de-Las-Casas C, Teixidó C, Cabrera C, Marín E, Vollmer I, Jares P, Garzón M, Molina-Vila MÁ, Reguart N.

Clin Lung Cancer. 2019 May;20(3):e219-e223. doi: 10.1016/j.cllc.2019.02.022. Epub 2019 Mar 4. No abstract available.

PMID:
30926357
6.

Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.

Clavé S, Rodon N, Pijuan L, Díaz O, Lorenzo M, Rocha P, Taus Á, Blanco R, Bosch-Barrera J, Reguart N, de la Torre N, Oliveras G, Espinet B, Bellosillo B, Puig X, Arriola E, Salido M.

Clin Lung Cancer. 2019 Jul;20(4):e421-e429. doi: 10.1016/j.cllc.2019.02.008. Epub 2019 Feb 26.

PMID:
30898567
7.

Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial.

Saint-Jean A, Reguart N, Eixarch A, Adán A, Castellà C, Sánchez-Dalmau B, Sainz-de-la-Maza M.

J Fr Ophtalmol. 2018 Dec;41(10):955-962. doi: 10.1016/j.jfo.2018.07.005. Epub 2018 Nov 23.

PMID:
30473235
8.

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018).

Majem M, Juan O, Insa A, Reguart N, Trigo JM, Carcereny E, García-Campelo R, García Y, Guirado M, Provencio M.

Clin Transl Oncol. 2019 Jan;21(1):3-17. doi: 10.1007/s12094-018-1978-1. Epub 2018 Nov 17.

9.

Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?

Remon J, Hendriks LE, Cabrera C, Reguart N, Besse B.

Cancer Treat Rev. 2018 Dec;71:47-58. doi: 10.1016/j.ctrv.2018.10.006. Epub 2018 Oct 15. Review.

PMID:
30359792
10.

EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).

Ruiz-Patiño A, Castro CD, Ricaurte LM, Cardona AF, Rojas L, Zatarain-Barrón ZL, Wills B, Reguart N, Carranza H, Vargas C, Otero J, Corrales L, Martín C, Archila P, Rodriguez J, Avila J, Bravo M, Pino LE, Rosell R, Arrieta O; Latin-American Consortium for the Investigation of Lung Cancer (CLICaP).

Target Oncol. 2018 Oct;13(5):621-629. doi: 10.1007/s11523-018-0594-x.

PMID:
30284706
11.

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types.

Paré L, Pascual T, Seguí E, Teixidó C, Gonzalez-Cao M, Galván P, Rodríguez A, González B, Cuatrecasas M, Pineda E, Torné A, Crespo G, Martin-Algarra S, Pérez-Ruiz E, Reig Ò, Viladot M, Font C, Adamo B, Vidal M, Gaba L, Muñoz M, Victoria I, Ruiz G, Viñolas N, Mellado B, Maurel J, Garcia-Corbacho J, Molina-Vila MÁ, Juan M, Llovet JM, Reguart N, Arance A, Prat A.

Ann Oncol. 2018 Oct 1;29(10):2121-2128. doi: 10.1093/annonc/mdy335.

PMID:
30165419
12.

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.

Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, Piñeyro D, Sanchez-Cespedes M, Girard N, Brevet M, Giroux-Leprieur E, Dumenil C, Pradotto M, Bironzo P, Capelletto E, Novello S, Cortot A, Copin MC, Karachaliou N, Gonzalez-Cao M, Peralta S, Montuenga LM, Gil-Bazo I, Baraibar I, Lozano MD, Varela M, Ruffinelli JC, Palmero R, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, Fernandez AF, Fraga MF, Gut M, Gut I, Teixidó C, Vilariño N, Prat A, Reguart N, Benito A, Garrido P, Barragan I, Emile JF, Rosell R, Brambilla E, Esteller M.

Lancet Respir Med. 2018 Oct;6(10):771-781. doi: 10.1016/S2213-2600(18)30284-4. Epub 2018 Aug 9.

13.

Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.

Remon J, Mezquita L, Corral J, Vilariño N, Reguart N.

J Thorac Dis. 2018 May;10(Suppl 13):S1516-S1533. doi: 10.21037/jtd.2017.12.52. Review.

14.

PD-L1 expression testing in non-small cell lung cancer.

Teixidó C, Vilariño N, Reyes R, Reguart N.

Ther Adv Med Oncol. 2018 Apr 11;10:1758835918763493. doi: 10.1177/1758835918763493. eCollection 2018. Review.

15.

Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions.

Remon J, Vilariño N, Reguart N.

Cancer Treat Rev. 2018 Mar;64:21-29. doi: 10.1016/j.ctrv.2018.02.002. Epub 2018 Feb 8. Review.

PMID:
29454155
16.

Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab.

Wills B, Cardona AF, Rojas L, Ruiz-Patiño A, Arrieta O, Reguart N, Carranza H, Vargas C, Otero J, Corrales L, Martín C, Cuello M, Pino LE, Rolfo C, Rosell R, Zatarain-Barrón ZL; Latin-American Consortium for the Investigation of Lung Cancer (CLICaP).

Anticancer Res. 2017 Nov;37(11):6429-6436.

PMID:
29061829
17.

Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions.

Mayo-de-Las-Casas C, Jordana-Ariza N, Garzón-Ibañez M, Balada-Bel A, Bertrán-Alamillo J, Viteri-Ramírez S, Reguart N, Muñoz-Quintana MA, Lianes-Barragan P, Camps C, Jantús E, Remon-Massip J, Calabuig S, Aguiar D, Gil ML, Viñolas N, Santos-Rodríguez AK, Majem M, García-Peláez B, Villatoro S, Pérez-Rosado A, Monasterio JC, Ovalle E, Catalán MJ, Campos R, Morales-Espinosa D, Martínez-Bueno A, González-Cao M, González X, Moya-Horno I, Sosa AE, Karachaliou N, Rosell R, Molina-Vila MA.

Ann Oncol. 2017 Sep 1;28(9):2248-2255. doi: 10.1093/annonc/mdx288.

PMID:
28911086
18.

Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients.

Gabasa M, Ikemori R, Hilberg F, Reguart N, Alcaraz J.

Br J Cancer. 2017 Oct 10;117(8):1128-1138. doi: 10.1038/bjc.2017.270. Epub 2017 Sep 12.

19.

A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.

Moran T, Palmero R, Provencio M, Insa A, Majem M, Reguart N, Bosch-Barrera J, Isla D, Costa EC, Lee C, Puig M, Kraemer S, Schnell D, Rosell R.

Lung Cancer. 2017 Jun;108:154-160. doi: 10.1016/j.lungcan.2017.03.009. Epub 2017 Mar 22.

PMID:
28625629
20.

Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).

Cardona AF, Arrieta O, Zapata MI, Rojas L, Wills B, Reguart N, Karachaliou N, Carranza H, Vargas C, Otero J, Archila P, Martín C, Corrales L, Cuello M, Ortiz C, Pino LE, Rosell R, Zatarain-Barrón ZL; CLICaP.

Target Oncol. 2017 Aug;12(4):513-523. doi: 10.1007/s11523-017-0497-2.

PMID:
28620690
21.

Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.

Chic N, Mayo-de-Las-Casas C, Reguart N.

J Thorac Oncol. 2017 Jun;12(6):e78-e80. doi: 10.1016/j.jtho.2017.02.014. No abstract available.

22.

Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis.

Batson S, Mitchell SA, Windisch R, Damonte E, Munk VC, Reguart N.

Onco Targets Ther. 2017 May 5;10:2473-2482. doi: 10.2147/OTT.S134382. eCollection 2017.

23.

Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.

Prat A, Navarro A, Paré L, Reguart N, Galván P, Pascual T, Martínez A, Nuciforo P, Comerma L, Alos L, Pardo N, Cedrés S, Fan C, Parker JS, Gaba L, Victoria I, Viñolas N, Vivancos A, Arance A, Felip E.

Cancer Res. 2017 Jul 1;77(13):3540-3550. doi: 10.1158/0008-5472.CAN-16-3556. Epub 2017 May 9.

24.

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.

Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA; BELIEF collaborative group.

Lancet Respir Med. 2017 May;5(5):435-444. doi: 10.1016/S2213-2600(17)30129-7. Epub 2017 Apr 10. Erratum in: Lancet Respir Med. 2018 Dec;6(12):e57.

PMID:
28408243
25.

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.

Chaib I, Karachaliou N, Pilotto S, Codony Servat J, Cai X, Li X, Drozdowskyj A, Servat CC, Yang J, Hu C, Cardona AF, Vivanco GL, Vergnenegre A, Sanchez JM, Provencio M, de Marinis F, Passaro A, Carcereny E, Reguart N, Campelo CG, Teixido C, Sperduti I, Rodriguez S, Lazzari C, Verlicchi A, de Aguirre I, Queralt C, Wei J, Estrada R, Puig de la Bellacasa R, Ramirez JL, Jacobson K, Ditzel HJ, Santarpia M, Viteri S, Molina MA, Zhou C, Cao P, Ma PC, Bivona TG, Rosell R.

J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx014.

26.

Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.

Reguart N, Teixidó C, Giménez-Capitán A, Paré L, Galván P, Viteri S, Rodríguez S, Peg V, Aldeguer E, Viñolas N, Remon J, Karachaliou N, Conde E, Lopez-Rios F, Nadal E, Merkelbach-Bruse S, Büttner R, Rosell R, Molina-Vila MA, Prat A.

Clin Chem. 2017 Mar;63(3):751-760. doi: 10.1373/clinchem.2016.265314. Epub 2017 Jan 10.

27.

BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations.

Cardona AF, Rojas L, Wills B, Arrieta O, Carranza H, Vargas C, Otero J, Corrales-Rodriguez L, Martín C, Reguart N, Archila P, Rodríguez J, Cuello M, Ortíz C, Franco S, Rolfo C, Rosell R, on behalf of the CLICaP.

Oncotarget. 2016 Sep 19;7(42):68933-68942. doi: 10.18632/oncotarget.12112.

28.

Heterotypic paracrine signaling drives fibroblast senescence and tumor progression of large cell carcinoma of the lung.

Lugo R, Gabasa M, Andriani F, Puig M, Facchinetti F, Ramírez J, Gómez-Caro A, Pastorino U, Fuster G, Almendros I, Gascón P, Davalos A, Reguart N, Roz L, Alcaraz J.

Oncotarget. 2016 Dec 13;7(50):82324-82337. doi: 10.18632/oncotarget.10327.

29.

ROS1 copy number alterations are frequent in non-small cell lung cancer.

Clavé S, Gimeno J, Muñoz-Mármol AM, Vidal J, Reguart N, Carcereny E, Pijuan L, Menéndez S, Taus Á, Mate JL, Serrano S, Albanell J, Espinet B, Arriola E, Salido M.

Oncotarget. 2016 Feb 16;7(7):8019-28. doi: 10.18632/oncotarget.6921.

30.

Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer.

Molina R, Marrades RM, Augé JM, Escudero JM, Viñolas N, Reguart N, Ramirez J, Filella X, Molins L, Agustí A.

Am J Respir Crit Care Med. 2016 Feb 15;193(4):427-37. doi: 10.1164/rccm.201404-0603OC.

PMID:
26465739
31.

Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts.

Vizoso M, Puig M, Carmona FJ, Maqueda M, Velásquez A, Gómez A, Labernadie A, Lugo R, Gabasa M, Rigat-Brugarolas LG, Trepat X, Ramírez J, Moran S, Vidal E, Reguart N, Perera A, Esteller M, Alcaraz J.

Carcinogenesis. 2015 Dec;36(12):1453-63. doi: 10.1093/carcin/bgv146. Epub 2015 Oct 7.

32.

Successful Oral Desensitization in a Patient With Hypersensitivity Reaction to Crizotinib.

Sánchez-López J, Viñolas N, Muñoz-Cano R, Pascal M, Reguart N, Bartra J, Valero A.

J Investig Allergol Clin Immunol. 2015;25(4):307-8. No abstract available.

33.

miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers.

Remon J, Alvarez-Berdugo D, Majem M, Moran T, Reguart N, Lianes P.

Clin Transl Oncol. 2016 Feb;18(2):153-9. doi: 10.1007/s12094-015-1347-2. Epub 2015 Jul 22.

PMID:
26199015
34.

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.

Karachaliou N, Mayo-de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, Garcia-Gomez R, Massuti B, Sánchez JM, Porta R, Ponce-Aix S, Moran T, Carcereny E, Felip E, Bover I, Insa A, Reguart N, Isla D, Vergnenegre A, de Marinis F, Gervais R, Corre R, Paz-Ares L, Morales-Espinosa D, Viteri S, Drozdowskyj A, Jordana-Ariza N, Ramirez-Serrano JL, Molina-Vila MA, Rosell R; Spanish Lung Cancer Group.

JAMA Oncol. 2015 May;1(2):149-57. doi: 10.1001/jamaoncol.2014.257.

PMID:
26181014
35.

Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.

Reguart N, Remon J.

Future Oncol. 2015;11(8):1245-57. doi: 10.2217/fon.15.15. Epub 2015 Jan 28. Review.

PMID:
25629371
36.

Interstitial lung disease arising from erlotinib treatment in a Caucasian patient.

Bugés C, Carcereny E, Moran T, Cardona AF, Reguart N, Capdevila L, Cros S, Rosell R.

Clin Lung Cancer. 2015 Mar;16(2):e1-3. doi: 10.1016/j.cllc.2014.11.003. Epub 2014 Nov 21. No abstract available.

PMID:
25550194
37.

[Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology].

Ferreirós J, Cabeza B, Gayete Á, Sánchez M, Torres MI, Cobo M, Isla D, Puente J, Reguart N, de Castro J.

Radiologia. 2015 Jan-Feb;57(1):66-78. doi: 10.1016/j.rx.2014.10.002. Epub 2014 Dec 17. Spanish.

38.

Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.

Remon J, Reguart N, Corral J, Lianes P.

Cancer Treat Rev. 2015 Jan;41(1):27-34. doi: 10.1016/j.ctrv.2014.10.007. Epub 2014 Nov 8. Review.

PMID:
25467107
39.

Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients.

Vidal J, Clavé S, de Muga S, González I, Pijuan L, Gimeno J, Remón J, Reguart N, Viñolas N, Gironés R, Bernet L, Majem M, Bosch-Barrera J, Porta R, Alonso N, Palmero R, Taus A, Albanell J, Espinet B, Salido M, Arriola E.

J Thorac Oncol. 2014 Dec;9(12):1816-20. doi: 10.1097/JTO.0000000000000361.

40.

Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology.

de Castro J, Cobo M, Isla D, Puente J, Reguart N, Cabeza B, Gayete A, Sánchez M, Torres MI, Ferreirós J.

Clin Transl Oncol. 2015 Jan;17(1):11-23. doi: 10.1007/s12094-014-1231-5. Epub 2014 Nov 6.

PMID:
25373531
41.

Matrix stiffening and β1 integrin drive subtype-specific fibroblast accumulation in lung cancer.

Puig M, Lugo R, Gabasa M, Giménez A, Velásquez A, Galgoczy R, Ramírez J, Gómez-Caro A, Busnadiego Ó, Rodríguez-Pascual F, Gascón P, Reguart N, Alcaraz J.

Mol Cancer Res. 2015 Jan;13(1):161-73. doi: 10.1158/1541-7786.MCR-14-0155. Epub 2014 Oct 3.

42.

Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry.

Conde E, Suárez-Gauthier A, Benito A, Garrido P, García-Campelo R, Biscuola M, Paz-Ares L, Hardisson D, de Castro J, Camacho MC, Rodriguez-Abreu D, Abdulkader I, Ramirez J, Reguart N, Salido M, Pijuán L, Arriola E, Sanz J, Folgueras V, Villanueva N, Gómez-Román J, Hidalgo M, López-Ríos F.

PLoS One. 2014 Sep 23;9(9):e107200. doi: 10.1371/journal.pone.0107200. eCollection 2014.

43.

Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel.

Arriola E, Reguart N, Artal A, Cobo M, García-Campelo R, Esteban E, Rodríguez MC, García-Muret MP.

Future Oncol. 2015;11(2):267-77. doi: 10.2217/fon.14.214. Epub 2014 Sep 19. Review.

PMID:
25236437
44.

Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.

Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, Buffoni L, Reguart N, Santos ES, Germonpre P, Taron M, Passiglia F, Van Meerbeeck JP, Russo A, Peeters M, Gil-Bazo I, Pauwels P, Rosell R.

Cancer Treat Rev. 2014 Sep;40(8):990-1004. doi: 10.1016/j.ctrv.2014.05.009. Epub 2014 Jun 6. Review.

PMID:
24953979
45.

Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcome.

Remon J, Morán T, Reguart N, Majem M, Carcereny E, Lianes P.

Cancer Treat Rev. 2014 Jul;40(6):723-9. doi: 10.1016/j.ctrv.2014.03.006. Epub 2014 Apr 12. Review.

PMID:
24759598
46.

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.

Reguart N, Rosell R, Cardenal F, Cardona AF, Isla D, Palmero R, Moran T, Rolfo C, Pallarès MC, Insa A, Carcereny E, Majem M, De Castro J, Queralt C, Molina MA, Taron M.

Lung Cancer. 2014 May;84(2):161-7. doi: 10.1016/j.lungcan.2014.02.011. Epub 2014 Mar 2.

PMID:
24636848
47.

Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor.

Rolfo C, Raez LE, Russo A, Reguart N, Campelo RG, Bronte G, Papadimitriou K, Silvestris F.

Expert Opin Biol Ther. 2014 Jan;14(1):15-26. doi: 10.1517/14712598.2013.843667. Epub 2013 Oct 28. Review.

PMID:
24161019
48.

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins.

Remon J, Morán T, Majem M, Reguart N, Dalmau E, Márquez-Medina D, Lianes P.

Cancer Treat Rev. 2014 Feb;40(1):93-101. doi: 10.1016/j.ctrv.2013.06.002. Epub 2013 Jul 3. Review.

PMID:
23829935
49.

Diarrhea associated with afatinib: an oral ErbB family blocker.

Yang JC, Reguart N, Barinoff J, Köhler J, Uttenreuther-Fischer M, Stammberger U, O'Brien D, Wolf J, Cohen EE.

Expert Rev Anticancer Ther. 2013 Jun;13(6):729-36. doi: 10.1586/era.13.31. Epub 2013 Mar 18. Review.

PMID:
23506556
50.

Integrin-specific mechanoresponses to compression and extension probed by cylindrical flat-ended AFM tips in lung cells.

Acerbi I, Luque T, Giménez A, Puig M, Reguart N, Farré R, Navajas D, Alcaraz J.

PLoS One. 2012;7(2):e32261. doi: 10.1371/journal.pone.0032261. Epub 2012 Feb 23.

Supplemental Content

Loading ...
Support Center